New nitric oxide-donating drugs for the treatment of airway diseases.
Nitric oxide (NO) is involved in many pathological and physiological processes in mammals, providing a possible biological basis for the use of NO replacement therapy in many conditions. A series of compounds have been synthesized in which an NO-releasing group has been linked to well-established parent molecules. This strategy has resulted in novel molecules with an improved profile of pharmacological activity, either in terms of enhanced therapeutic efficacy or reduced side effects. This review examines the biological significance, mechanism(s) of action and therapeutic potential of such compounds in respiratory disease.
Lagente
Vincent
V
INSERM U620, 2 Avenue du Professeur Léon Bernard, Université de Rennes 1, 35043 Rennes, France. vincent.lagente@rennes.inserm.fr
Advenier
Charles
C
D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000420:Albuterol / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D020030:Nitric Oxide Donors / Q000494:pharmacology / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D020030:Nitric Oxide Donors; D009569:Nitric Oxide; D000420:Albuterol